Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. (AUPH) is a biopharmaceutical innovator developing therapies for autoimmune diseases with high unmet needs, including lupus nephritis. This page aggregates all company announcements, clinical trial updates, and regulatory developments.
Investors and healthcare professionals will find real-time access to earnings reports, partnership disclosures, and research milestones. Key coverage areas: FDA submissions, therapy commercialization progress, and scientific collaboration updates related to LUPKYNIS and pipeline candidates.
Bookmark this resource for verified information directly from corporate communications and curated third-party analysis. Check regularly for developments impacting Aurinia's position in autoimmune treatment markets.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has launched the 'Get Uncomfortable' campaign featuring Toni Braxton, aimed at raising awareness about lupus nephritis and the importance of kidney health. The initiative encourages individuals with lupus nephritis to undergo routine testing and regular doctor visits to prevent irreversible kidney damage. Braxton, diagnosed with lupus in 2008, shares her personal experience to inspire others to advocate for their health. Since its inception in October 2022, the campaign has reached numerous patients, providing critical information regarding kidney health. Notably, lupus nephritis disproportionately affects women of color, emphasizing the need for increased awareness and action.
Shareholder MKT Capital Ltd., owning 4.2% of Aurinia Pharmaceuticals (AUPH), has publicly criticized the company’s management for their poor performance and excessive executive compensation, including a total of
FAQ
What is the current stock price of Aurinia Pharmace (AUPH)?
What is the market cap of Aurinia Pharmace (AUPH)?
